3 Best Stocks to Buy Now, 9/11/2025 - Top Analysts Reveal Their Picks

Wall Street's sharpest minds just dropped their hottest stock picks—and these three names are dominating the conversation.

Breaking Down the Analyst Consensus

Forget the noise. Top analysts are converging on three standout equities that combine strong fundamentals with explosive growth potential. These aren't your grandfather's blue chips—they're positioned to outperform in today's volatile market.

Why These Stocks Matter Now

Each pick represents a strategic play on emerging trends that traditional finance still hasn't fully priced in. We're talking about companies leveraging AI, blockchain infrastructure, and quantum computing—not just riding hype cycles.

The Bottom Line

While your fund manager might still be arguing about interest rates, these analysts are betting on actual innovation. Because sometimes the best trade is ignoring the conventional wisdom altogether.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts. 

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

 (ONON) – On Holding is a Swiss sportswear brand best known for its performance running shoes and apparel. Yesterday, Morgan Stanley analyst Alexandra Straton maintained a Buy rating on the stock with a price target of $65 per share. In the last three months, all 13 Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 57.13%.

(CATX) – Perspective Therapeutics is a biotech firm working on targeted radiation drugs to treat cancer. Yesterday, B. Riley Financial analyst Yuan Zhi maintained a Buy rating on the stock with a price target of $12 per share. In the last three months, all five Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 333.44%.

(TVRD) – Tvardi Therapeutics is a biotech company developing oral drugs to treat cancer and fibrosis. Yesterday, Raymond James analyst Ryan Deschner maintained a Buy rating on the stock and increased the price target to $62 from $31.82 per share. In the last three months, all five Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 84.53%.

Who Are the Top Analysts? 

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time. 

Disclosure